MET and hepatocellular carcinoma: The enhanced expression of c-Met has been observed in various tumors, such as breast cancer [17], lung cancer [18], gastric cancer [19], colorectal cancer [20], cervix cancer [21], pancreatic cancer [22], and hepatocellular carcinoma [23].